SCYNEXIS, Inc.
SCYXSCYNEXIS, Inc. is a biopharmaceutical company focused on developing and commercializing innovative antifungal therapies. It is known for its oral antifungal drug, Brexafemme (ibrexafungerp), which is approved for the treatment of certain fungal infections. The company emphasizes research and development to address unmet medical needs in fungal diseases and expand its portfolio of antifungal agents.
Company News
U.S. stock futures rose on Tuesday following Memorial Day, with the S&P 500 and Nasdaq 100 gaining 0.52% and 0.73% respectively. Despite U.S. defensive strikes on Iranian missile sites, markets remained resilient as oil prices fell and Iran negotiations progressed. Key movers included Elbit Systems jumping 8.26% on a $1.4B military contract, Intu...
SCYNEXIS, Inc. approved inducement equity awards for a new Vice President on April 30, 2026, consisting of stock options to purchase 125,000 shares at $0.93 per share and 20,000 restricted stock units. The awards were granted under the company's 2015 Inducement Award Plan in accordance with Nasdaq regulations.
SCYNEXIS announced the completion of its acquisition of PXL-770 (now SCY-770), a novel AMPK activator for treating ADPKD, the leading genetic cause of end-stage renal failure. Under the deal, SCYNEXIS will pay $8 million upfront with up to $188 million in potential milestone payments. The company plans to initiate a Phase 2 proof-of-concept study...
SCYNEXIS has transferred its BREXAFEMME New Drug Application to GSK, enabling potential regulatory interactions for relaunching the drug for vulvovaginal candidiasis. SCYNEXIS will receive potential net sales milestones and royalties from GSK.
A leading company engaged DelveInsight to conduct a comprehensive study on the myopia market, including prevalence, treatment patterns, and market forecasts across the APAC region. DelveInsight's analysis provided strategic insights to help the client optimize its market entry and differentiation strategies.
